Advanced search
1 file | 932.36 KB

Matrix metalloproteinases as drug targets in ischemia/reperfusion injury

(2011) DRUG DISCOVERY TODAY. 16(17-18). p.762-778
Author
Organization
Abstract
Deficient blood supply (ischemia) is a common consequence of some surgical procedures and certain pathologies. Once blood circulation is reestablished (reperfusion), a complex series of events results in recruitment of inflammatory cells, rearrangement of the extracellular matrix and induction of cell death, which lead to organ dysfunction. Although ischemia/reperfusion (I/R) injury is an important cause of death, there is no effective therapy targeting the molecular mechanism of disease progression. Matrix metalloproteinases (MMPs), which are important regulators of many cellular activities, have a central role in disease progression after I/R injury, as suggested by numerous studies using MMP inhibitors or MMP-deficient mice. Here, we review the involvement of MMP activity in the various processes following I/R injury and the therapeutic potential of MMP inhibition.
Keywords
TISSUE-PLASMINOGEN ACTIVATOR, EXPERIMENTAL MYOCARDIAL-INFARCTION, BLOOD-BRAIN-BARRIER, FOCAL CEREBRAL-ISCHEMIA, SINUSOIDAL ENDOTHELIAL-CELLS, LEFT-VENTRICULAR ENLARGEMENT, PREVENTS CARDIAC RUPTURE, TIME-DEPENDENT CHANGES, ISOLATED RAT HEARTS, MYOSIN LIGHT-CHAIN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 932.36 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Dejonckheere, Eline, Roosmarijn Vandenbroucke, and Claude Libert. 2011. “Matrix Metalloproteinases as Drug Targets in Ischemia/reperfusion Injury.” Drug Discovery Today 16 (17-18): 762–778.
APA
Dejonckheere, E., Vandenbroucke, R., & Libert, C. (2011). Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. DRUG DISCOVERY TODAY, 16(17-18), 762–778.
Vancouver
1.
Dejonckheere E, Vandenbroucke R, Libert C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. DRUG DISCOVERY TODAY. 2011;16(17-18):762–78.
MLA
Dejonckheere, Eline, Roosmarijn Vandenbroucke, and Claude Libert. “Matrix Metalloproteinases as Drug Targets in Ischemia/reperfusion Injury.” DRUG DISCOVERY TODAY 16.17-18 (2011): 762–778. Print.
@article{1933692,
  abstract     = {Deficient blood supply (ischemia) is a common consequence of some surgical procedures and certain pathologies. Once blood circulation is reestablished (reperfusion), a complex series of events results in recruitment of inflammatory cells, rearrangement of the extracellular matrix and induction of cell death, which lead to organ dysfunction. Although ischemia/reperfusion (I/R) injury is an important cause of death, there is no effective therapy targeting the molecular mechanism of disease progression. Matrix metalloproteinases (MMPs), which are important regulators of many cellular activities, have a central role in disease progression after I/R injury, as suggested by numerous studies using MMP inhibitors or MMP-deficient mice. Here, we review the involvement of MMP activity in the various processes following I/R injury and the therapeutic potential of MMP inhibition.},
  author       = {Dejonckheere, Eline and Vandenbroucke, Roosmarijn and Libert, Claude},
  issn         = {1359-6446},
  journal      = {DRUG DISCOVERY TODAY},
  language     = {eng},
  number       = {17-18},
  pages        = {762--778},
  title        = {Matrix metalloproteinases as drug targets in ischemia/reperfusion injury},
  url          = {http://dx.doi.org/10.1016/j.drudis.2011.06.009},
  volume       = {16},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: